Beijing Biostar FY26 H1 net loss narrows to RMB 26.6 million; revenue more than doubles to RMB 36.64 million

PUBT · 1d ago
Beijing Biostar FY26 H1 net loss narrows to RMB 26.6 million; revenue more than doubles to RMB 36.64 million
  • Beijing Biostar Pharmaceuticals posted revenue of RMB 36.64 million, more than doubled year over year.
  • Net loss narrowed 50.8% to RMB 26.6 million; loss per share improved to RMB 0.07.
  • R&D expenses fell 53.9% to RMB 19.06 million, due to lower clinical and technical service spending.
  • Sales expenses dropped 18.6% to RMB 15.9 million, while administrative expenses climbed 28.2% to RMB 18.24 million.
  • Utidelone Injection sales volume rose on wider market coverage; Phase III neoadjuvant breast cancer enrollment neared 90%, with NDA targeted in H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12301397), on August 26, 2026, and is solely responsible for the information contained therein.